Novartis (Ireland)

Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)—a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US

Tyrosine kinase inhibitors (TKIs) improve survival for people with chronic myeloid leukemia (CML) but may cause adverse events (AEs) that impair quality of life (QoL). Adults with CML receiving first- or second-line TKI therapy in the United States (US) completed validated questi...